Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peanut Protein Clear all

Conditions: Peanut Allergy
Interventions: Dupilumab, Placebo matching dupilumab, AR101; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more

Conditions: Food Allergy, Peanut Allergy
Interventions: Peanut Protein, Continued peanut avoidance; Biological · Other
Lead sponsor: Scott Sicherer; Other
Eligibility: 4 Years to 14 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Protein Metabolism
Interventions: Red kidney bean intake, Eggs intake, Peanut butter intake, Ground beef intake, Intact beef intake; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 20 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Peanut Allergy
Interventions: AR101 powder provided in capsules, Placebo powder provided in capsules; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Parkinson's Disease
Interventions: Trans-Resveratrol; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 250 mcg; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 7 Years to 56 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: San Diego, California • Stanford, California • Chicago, Illinois + 6 more

Conditions: Surgery
Interventions: Peanut Protein Powder, Standard Care by Surgeon and Physical Therapist; Dietary Supplement · Other
Lead sponsor: Auburn University; Other
Eligibility: 60 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Food Allergy, Peanut Allergy
Interventions: omalizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Appetitive Behavior
Interventions: Pea Protein-20g, Pea Protein-30g, Pea Protein-40g, Whey Protein-20g, Carbohydrate Control; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 20 Years to 40 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Peanut Allergic Subjects
Interventions: Peanut Oral Immunotherapy (POIT); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 16 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peanut Allergy, Multi-food Allergy
Interventions: Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 55 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more

Conditions: Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions: Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Peanut Allergy
Interventions: Whole peanut extract, Placebo formulation; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more

Conditions: Peanut Hypersensitivity
Interventions: Boiled Peanut Powder; Drug
Lead sponsor: Alton Melton; Other
Eligibility: 1 Year to 16 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Allergy
Interventions: Xolair (omalizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Food Allergy, Food Allergy Peanut
Interventions: Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT), Placebo (in place of antibiotics), Oral Immunotherapy (OIT); Biological · Drug · Other
Lead sponsor: Rima Rachid; Other
Eligibility: 12 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Food Allergy
Interventions: Food Supplement; Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 5 Months to 11 Months
Enrollment: 705 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Peanut Hypersensitivity, Food Allergy, Food Hypersensitivity, Peanut Allergy
Interventions: Liquid Peanut Extract, Placebo Glycerin SLIT; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Months to 48 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Dallas, Texas

Conditions: Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions: Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 55 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California

Conditions: Peanut Allergy
Interventions: AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 49
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more

Conditions: Allergy
Interventions: Oral Food Challenge (OFC): Peanut Protein; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Months to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more

Conditions: Peanut Allergy
Interventions: AR101 - Peanut protein capsule; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Peanut Hypersensitivity
Interventions: Peanut protein; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 16 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 250mcg, Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more

Search by objective public record fields.

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

Are the "ounce-equivalents" in the Protein Foods Groups Really Equivalent?

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

RESvEraTrol in Parkinson's Disease (RESET)

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

Peanut Protein Supplementation to Prevent Muscle Atrophy and Improve Recovery Following Total Knee Arthroplasty

Omalizumab in the Treatment of Peanut Allergy

The Effects of Protein Source on Appetite Control, Satiety, and Subsequent Food Intake: A Clinical Screening Study

Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Boiled Peanut Oral Immunotherapy

A Safety and Efficacy Study of Xolair in Peanut Allergy

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals

FARE Peanut SLIT and Early Tolerance Induction

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Study of Oral Food Challenge Biomarkers (SAFER)

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Oral Peanut Immunotherapy for Peanut Allergic Patients

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy